Logo image of MXCT

MAXCYTE INC (MXCT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MXCT - US57777K1060 - Common Stock

1.55 USD
+0.08 (+5.44%)
Last: 12/8/2025, 8:28:33 PM
Fundamental Rating

3

Overall MXCT gets a fundamental rating of 3 out of 10. We evaluated MXCT against 57 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for MXCT as it has an excellent financial health rating, but there are worries on the profitability. MXCT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MXCT had negative earnings in the past year.
In the past year MXCT has reported a negative cash flow from operations.
In the past 5 years MXCT always reported negative net income.
MXCT had a negative operating cash flow in each of the past 5 years.
MXCT Yearly Net Income VS EBIT VS OCF VS FCFMXCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

MXCT has a worse Return On Assets (-20.37%) than 64.91% of its industry peers.
MXCT has a Return On Equity of -23.47%. This is comparable to the rest of the industry: MXCT outperforms 45.61% of its industry peers.
Industry RankSector Rank
ROA -20.37%
ROE -23.47%
ROIC N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
MXCT Yearly ROA, ROE, ROICMXCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

MXCT has a Gross Margin of 79.79%. This is amongst the best in the industry. MXCT outperforms 100.00% of its industry peers.
MXCT's Gross Margin has declined in the last couple of years.
MXCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
MXCT Yearly Profit, Operating, Gross MarginsMXCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

7

2. Health

2.1 Basic Checks

MXCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MXCT has more shares outstanding
MXCT has more shares outstanding than it did 5 years ago.
MXCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MXCT Yearly Shares OutstandingMXCT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
MXCT Yearly Total Debt VS Total AssetsMXCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

MXCT has an Altman-Z score of 1.81. This is a bad value and indicates that MXCT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MXCT (1.81) is comparable to the rest of the industry.
There is no outstanding debt for MXCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.81
ROIC/WACCN/A
WACC10.42%
MXCT Yearly LT Debt VS Equity VS FCFMXCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 12.39 indicates that MXCT has no problem at all paying its short term obligations.
MXCT's Current ratio of 12.39 is amongst the best of the industry. MXCT outperforms 94.74% of its industry peers.
MXCT has a Quick Ratio of 11.71. This indicates that MXCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.71, MXCT belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.39
Quick Ratio 11.71
MXCT Yearly Current Assets VS Current LiabilitesMXCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for MXCT have decreased strongly by -20.59% in the last year.
The Revenue has decreased by -6.44% in the past year.
The Revenue has been growing by 12.31% on average over the past years. This is quite good.
EPS 1Y (TTM)-20.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
Revenue 1Y (TTM)-6.44%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-16.35%

3.2 Future

MXCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.36% yearly.
The Revenue is expected to grow by 20.40% on average over the next years. This is a very strong growth
EPS Next Y-4.09%
EPS Next 2Y14.13%
EPS Next 3Y13.66%
EPS Next 5Y11.36%
Revenue Next Year-6.11%
Revenue Next 2Y1.95%
Revenue Next 3Y9.01%
Revenue Next 5Y20.4%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MXCT Yearly Revenue VS EstimatesMXCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
MXCT Yearly EPS VS EstimatesMXCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MXCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MXCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MXCT Price Earnings VS Forward Price EarningsMXCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MXCT Per share dataMXCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as MXCT's earnings are expected to grow with 13.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.13%
EPS Next 3Y13.66%

More info and screens

0

5. Dividend

5.1 Amount

MXCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAXCYTE INC

NASDAQ:MXCT (12/8/2025, 8:28:33 PM)

1.55

+0.08 (+5.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners70.79%
Inst Owner Change-5.07%
Ins Owners1.32%
Ins Owner Change4.66%
Market Cap165.34M
Revenue(TTM)38.63M
Net Income(TTM)-44.77M
Analysts83.08
Price Target6.47 (317.42%)
Short Float %3.02%
Short Ratio3.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.61%
Min EPS beat(2)-13.86%
Max EPS beat(2)6.63%
EPS beat(4)3
Avg EPS beat(4)6.24%
Min EPS beat(4)-13.86%
Max EPS beat(4)19.64%
EPS beat(8)6
Avg EPS beat(8)14.2%
EPS beat(12)9
Avg EPS beat(12)14.45%
EPS beat(16)13
Avg EPS beat(16)16.81%
Revenue beat(2)1
Avg Revenue beat(2)-3.6%
Min Revenue beat(2)-12.47%
Max Revenue beat(2)5.28%
Revenue beat(4)3
Avg Revenue beat(4)2.21%
Min Revenue beat(4)-12.47%
Max Revenue beat(4)8.53%
Revenue beat(8)6
Avg Revenue beat(8)11.35%
Revenue beat(12)8
Avg Revenue beat(12)5.7%
Revenue beat(16)12
Avg Revenue beat(16)9.06%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.51%
EPS NY rev (1m)6.72%
EPS NY rev (3m)5.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-2.3%
Revenue NY rev (3m)-2.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.62
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.89
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.34
BVpS1.79
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.37%
ROE -23.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.79%
FCFM N/A
ROA(3y)-13.17%
ROA(5y)-13.81%
ROE(3y)-15.17%
ROE(5y)-17.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y-1.59%
F-Score2
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.44%
Cap/Sales 5.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.39
Quick Ratio 11.71
Altman-Z 1.81
F-Score2
WACC10.42%
ROIC/WACCN/A
Cap/Depr(3y)270.47%
Cap/Depr(5y)255.66%
Cap/Sales(3y)18.33%
Cap/Sales(5y)14.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.18%
EPS Next Y-4.09%
EPS Next 2Y14.13%
EPS Next 3Y13.66%
EPS Next 5Y11.36%
Revenue 1Y (TTM)-6.44%
Revenue growth 3Y4.46%
Revenue growth 5Y12.31%
Sales Q2Q%-16.35%
Revenue Next Year-6.11%
Revenue Next 2Y1.95%
Revenue Next 3Y9.01%
Revenue Next 5Y20.4%
EBIT growth 1Y-13.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.57%
EBIT Next 3Y15.85%
EBIT Next 5Y12.68%
FCF growth 1Y-11.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.01%
OCF growth 3YN/A
OCF growth 5YN/A

MAXCYTE INC / MXCT FAQ

What is the fundamental rating for MXCT stock?

ChartMill assigns a fundamental rating of 3 / 10 to MXCT.


What is the valuation status of MAXCYTE INC (MXCT) stock?

ChartMill assigns a valuation rating of 0 / 10 to MAXCYTE INC (MXCT). This can be considered as Overvalued.


How profitable is MAXCYTE INC (MXCT) stock?

MAXCYTE INC (MXCT) has a profitability rating of 1 / 10.


What is the financial health of MAXCYTE INC (MXCT) stock?

The financial health rating of MAXCYTE INC (MXCT) is 7 / 10.